After traveling around Europe with management, Piper Jaffray analyst Danielle Brill believes Sarepta Therapeutics' key programs are "progressing nicely" despite the recent selloff in the shares. The microdystrophin gene therapy program is on-track and Sarepta's "confidence is clear," Brill tells investors in a research note. Further, the company is moving the LGMD2E gene therapy program "right along" and it plans to work with the FDA to determine a path forward for Golodirsen, adds the analyst. She keeps an Overweight rating on Sarepta shares with a $185 price target.